Chembio announces fda clia waiver submission for dpp hiv-syphilis system

Hauppauge, n.y., nov. 28, 2022 (globe newswire) -- chembio diagnostics, inc. (nasdaq: cemi), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the u.s. food and drug administration (fda) for a clinical laboratory improvement amendments (clia) waiver for the dpp hiv-syphilis system.
CEMI Ratings Summary
CEMI Quant Ranking